A 68-year-old woman presents with a new 6-mm nodule with central ulceration and a rolled border on the right cheek. What's your diagnosis? How would you treat?
A 68-year-old female with a history of basal cell carcinoma presents to your office concerned about a new facial lesion she noticed about 6 months ago. You note a 6-mm shiny, skin-colored-to-pink nodule with central ulceration and a rolled border on the right malar cheek, temporal area. She has fair skin color and moderate to severe photo damage.
Based on this presentation, what is the most likely diagnosis?A. Actinic keratosis
B. Seborrheic keratosis
C. Traumatized intradermal nevus
D. Nodular basal cell carcinoma
E. Superficial basal cell carcinoma
F. Hydrocystoma
Please click here for answer and discussion.
Answer: D. Nodular basal cell cacrinoma. The lesion described is a basal cell carcinoma (BCC), a tumor found on sun damaged skin that is relatively easily recognized during routine skin examination. BCC is more common than all other human malignancies combined and its incidence continues to rise, with more than 2.8 million new cases of BCC diagnosed annually in the United States.1
The main clinical subtypes of BCC include nodular BCC accounting for 50-79% of all BCCs, followed by superficial BCC accounting for up to 15% of BCCs, and morpheaform BCC estimated at 5-10% of BCC cases.2
Nodular BCC presents as pink to pearly shiny papules or nodules often with telangiectasia and ulceration.3 Initially the lesions have a smooth surface, but with time they enlarge and ulcerate to form an elevated, rolled border.3
Risk factors for BCC include those of other skin cancers namely sun exposure, fair complexion, light eyes, and increasing age.4 Intermittent, intense UVB exposure is the greatest risk factor, but other risk factors include chronic immunosuppression, radiation therapy, and arsenic exposure.5
Next: Is a biopsy required?
BCC can appear on any part of the body. Mainly it is found in areas with extensive sun exposure, with about 80% located on the head and neck.6 Clinical diagnosis can be quite sensitive and specific for BCC, however a biopsy is required for confirmation and classification of histologic subtype, which predicts behavior and has implications for therapeutic decision making.5
Metastases of BCC are rare, but treatment is indicated due to the destruction of local tissue and locally invasive activity.4
Multiple treatment modalities are available for BCC; which of the following is recommended?
A. Moh’s micrographic surgery (MMS)
B. Cryotherapy
C. Simple excision with 3mm margin
D. Electrodessication and curettage
E. 5-fluorouracil topical therapy
Please click here for answer and discussion.
Answer: A. Moh's micrographic surgery. MMS is a dermatologic surgery technique that optimizes margin control and tissue conservation and is the first line treatment of BCC that is high risk for recurrence or for optimal preservation of function and cosmesis.7 A combination of factors including anatomic location, histologic features, primary or recurrent tumors, and patient characteristics influence the choice of treatment.7
1. Mohan SV, Chang ALS. Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations. Current Dermatology Reports. 2014;3(1):40-45.
2.Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. The Yale journal of biology and medicine. 2015;88(2):167-179.
3.Bolognia J, Jorizzo JL, Schaffer JV. Dermatology. [Philadelphia]: Elsevier Saunders; 2012.
4.Linares MA, Zakaria A, Nizran P. Skin Cancer. Primary care. 2015;42(4):645-659.
5. Gandhi SA, Kampp J. Skin Cancer Epidemiology, Detection, and Management. The Medical clinics of North America. 2015;99(6):1323-1335.
6. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ (Clinical research ed.). 2003;327(7418):794-798.
7. Lewin JM, Carucci JA. Advances in the management of basal cell carcinoma. F1000prime reports. 2015;7:53.
8. app. AAoDMSA-pUCA. https://www.aad.org/members/aad-apps/mohs-auc.
9.Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. Journal of the American Academy of Dermatology. 2012;67:531-550.
3 Reasons Urology Practices Should Add Onsite UTI PCR Labs Under New LCD Rules
March 11th 20251. ONSITE PCR TESTING BRINGS SIGNIFICANT CLINICAL BENEFITS TO A PRACTICE. - ACCURACY Traditional urine cultures can give false-negative results. - SPECIFICITY Accurate microbial identification leads to targeted treatment. - SPEED Same day results vs. 3-5 days for traditional urine cultures - - - ANTIBIOTIC RESISTANCE MARKERS Improves antimicrobial stewardship 2. MAINTAIN INDEPENDENCE BY INCREASING REVENUE SIGNIFICANTLY THROUGH REVENUE SHIFTING FROM THE REFERENCE LAB TO THE PRACTICE. - Turnkey: Consultation on COLA and CLIA certification, all necessary equipment, standard operating procedures, personnel sourcing and interview, billing and coding training, 3-4 days of onsite training. - Stark Law Compliant: Complies with anti-kickback statutes. - Medicare part B pays at 100%, Med Advantage Plans at 80% - No lab build-out, only 8 linear feet of counter space needed - Z-code procurement for required states 3. BETTER PATIENT CARE LEADS TO BETTER OUTCOMES. - CONVENIENCE Point of care, no third-party referral lab. - TIMELY Results early in the care process. - CORRECT MEDICATION Avoids two trips to the pharmacy. - BETTER OUTCOMES Reduction of recurrent UTI and hospitalizations